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Introduction: Awake craniotomy allows continuous monitoring of patients’ neurological 
functions during open surgery. Anesthesiologists have to sedate patients in a way so that they 
are compliant throughout the whole surgical procedure, nevertheless maintaining adequate 
analgesia and anxiolysis. Currently, the use of α2-receptor agonist dexmedetomidine as the 
primary hypnotic–sedative medication is increasing.
Methods: Nine patients undergoing awake craniotomy were treated with refined monitored 
anesthesia care (MAC) protocol consisting of a combination of local anesthesia without scalp 
block, low-dose infusion of dexmedetomidine, propofol, and remifentanil, without the need of 
airways management.
Results: The anesthetic protocol applied in our study has the advantage of decreasing the dose 
of each drug and thus reducing the occurrence of side effects. All patients had smooth and rapid 
awakenings. The brain remained relaxed during the entire procedure.
Conclusion: In our experience, this protocol is safe and effective during awake brain surgery. 
Nevertheless, prospective randomized trials are necessary to confirm the optimal anesthetic 
technique to be used.
Keywords: dexmedetomidine, awake surgery, anesthesia
Abbreviations
bpm, beats per minute; DEX, dexmedetomidine; EcoG, electrocorticography; HR, 
heart rate; LMA, laryngeal mask airway; MAC, monitored anesthesia care; MAP, mean 
arterial pressure; MEPs, motor evoked potentials; PRO, propofol; REM, remifentanil; 
SEPs, somatosensory evoked potentials.
Introduction
Awake craniotomy enables neurosurgeons to continuously monitor the patient’s 
neurological functions during open surgery.
Anesthesiologists are required to maintain the patient’s cooperation along with 
adequate sedation, analgesia, and anxiolysis throughout the whole procedure. Although 
awake craniotomy procedures have become common in neurosurgical practice, there is 
still no consensus on the optimal pharmacological regimen during the intervention.
The use of α2-receptor agonist DEX as primary hypnotic–sedative medication 
is common nowadays, especially in intensive care unit settings, because it provides 
effective and safe conscious sedation.
DEX rapidly acts on the pontine locus coeruleus, providing subcortical sedation 
characterized by a comfortable and quick arousal, with minimal effect on the respi-
ratory drive. Bradycardia and moderate hypotension are the most common hemo-
dynamic effects.
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We describe the anesthetic management of patients 
who underwent awake craniotomies at our institution 
(NOCSAE Modena Hospital, Modena, Italy). A combina-
tion of DEX, PRO, and REM was used without any need for 
airway instrumentation.
Methods
Population
We retrospectively reviewed all awake craniotomies per-
formed with MAC protocol at our institution from May 2013 
to December 2014. We identified 9 patients (5 males and 
4 females) meeting the inclusion criteria. They underwent 
craniotomy to remove 7 gliomas, 1 meningioma, and 
1 cavernoma. Unfavorable anatomical features such as short 
neck or overweight were not considered exclusion criteria. 
Data regarding anesthetic technique, vital parameters, and 
patients’ outcome were collected.
The most involved locations were the middle frontal 
gyrus, the middle temporal gyrus, the precentral gyrus, the 
inferior frontal gyrus, the angular gyrus, and the superior 
temporal gyrus.
Patients’ demographics and pathological characteristics 
are shown in Table 1.
A neuropsychologist instructed the patients to perform 
the neurological examination during surgery.
The official institutional board (Modena Local Health 
Authority – Internal Review Board) approved the study. 
Patient consent was not required by the institutional board 
to review medical records.
anesthetic and surgical procedures
All patients underwent awake craniotomy using the MAC 
protocol.
Ranitidine 50 mg and metoclopramide 10 mg were 
administered 2 h before induction of anesthesia to prevent 
nausea and vomiting.
After electrocardiography, pulse oximetry, noninvasive 
blood pressure monitoring, and double peripheral venous 
cannulation, we started the simultaneous infusion of DEX, 
PRO, and REM.
Radial artery-line, Foley catheter, and an additional 
peripheral intravenous catheter were placed after induction 
of anesthesia.
Initial DEX dose of 0.7 μg/kg/h was followed by 
0.2–1.4 μg/kg/h maintenance infusion. No loading dose was 
used, and infusion rate was progressively increased until 
adequate sedation was obtained. We used Ramsay sedation 
score to assess the level of sedation every 90 s. A Ramsey 
sedation score between 4 and 6 was considered adequate. 
It was reached by slowly increasing the DEX infusion to 
0.2 μg/kg, unless the HR decreased to 50 bpm or the MAP 
decreased to 60 mmHg. In case of persistently inadequate 
sedation despite these adjustments, we increased the concen-
tration of the PRO infusion.
All patients had spontaneous ventilation with supplemen-
tal oxygen (2 L/min) through a capnomask (Mediplus, Bucks, 
UK). No laryngeal mask or other devices were used.
A 3-pin head-holder was placed on the patient under 
local anesthesia with subcutaneous injection of bupivacaine 
with epinephrine (1:200,000) and ropivacaine 7.5 mg/mL, 
without nerve block.
Comfortable positioning of the patient was achieved, 
keeping the head slightly elevated in order not to compress 
jugular venous flow. Such positioning prevents airway occlu-
sion during the asleep period, especially in patients with 
anatomically unfavorable neck.
Patients underwent EcoG using a 32-channel Nicolet alli-
ance portable unit (Nicolet BMSI, Inc, Madison, WI, USA). 
Standard MEPs and SEPs were recorded.
Surgical incision was planned using neuronavigation in 
order to expose both the tumor and the surrounding cortical 
eloquent areas. A solution of bupivacaine with epineph-
rine (1:200,000) and ropivacaine 7.5 mg/mL was used for 
local anesthesia.
Draping was adjusted to keep eyes and airways easily 
accessible.
Table 1 Patient demographics and clinicopathological characteristics
Number Age, years Sex Previous history Pathology Grade Location (gyrus)
1 48 M glaucoma glioma iV Posterior T2–T3
2 57 F hypertension Meningioma i Precentral–F3
3 56 F hypertension, obesity, 
diabetes mellitus type 2
glioma iii Posterior F1
4 62 F Dyslipidemia glioma ii F2
5 30 M none glioma ii Precentral
6 31 F none cavernoma F2
7 41 M none glioma ii T2–angular
Abbreviations: F, female; M, male.
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Dexmedetomidine in awake craniotomy
The patient was maintained asleep during scalp incision, 
bone flap removal, and dural opening. Dura mater was soaked 
with lidocaine 10% before incision.
After brain exposure, all drugs were stopped, and the 
patient progressively awakened. The surgeon gave ongoing 
feedback to the anesthesiologist regarding the brain appear-
ance, in order to maintain the brain relaxed.
Cortical mapping was achieved using Ojemann cortical 
stimulator (Radionics Corp, Burlington, MA, USA) with a 
monopolar probe, delivering stimuli with a single 1 ms pulse 
with a 60 Hz frequency. Skill tests were performed during 
surgical resection.
Analgesics (acetaminophen 1 g) were added when 
needed.
When resection adjacent to functionally relevant areas 
was completed, anesthesia was reinduced with DEX, PRO, 
and REM infusions titrated to patient sedation level.
Patients spontaneously breathed throughout the whole 
procedure without the aid of a laryngeal mask.
After wound closure, all anesthetics were stopped, allowing 
the patient to awaken from anesthesia in the operative theater. 
All patients were admitted to the subintensive care unit.
Results
Table 2 summarizes the drug infusion doses, HR, arterial blood 
pressure, MAP, awakening periods, and length of anesthesia.
From induction to awakening, DEX, PRO, and REM infu-
sion doses ranged between 0.28 and 0.90 μg/kg/h, 0.51 and 
1.26 mg/kg/h, and 0.02 and 0.05 μg/kg/min, respectively.
We observed HR and MAP decrease as expected; however, 
their values were never less than 50 bpm and 60 mmHg, 
respectively.
EcoG confirmed appropriate patient sedation.
After stopping drug infusion, the patients were able to col-
laborate for an average period of 10 min. The awakening was 
always smooth, resembling natural awakening. Moreover, 
as we avoided the use of a laryngeal mask and other airway 
devices, we did not observe any coughing.
The awakening period lasted on average 77 min (range: 
40–120 min). Three patients required additional analgesia 
(acetaminophen 1 g).
Drugs infusion doses during the final part of the operation 
ranged between 0.23 and 0.91 μg/kg/h for DEX, 0.2 and 
1.45 mg/kg/h for PRO, and 0.04 and 0.08 μg/kg/min for 
REM. Similar to the previous asleep period, we did not 
observe critical levels of HR and MAP.
After surgery, all patients reached an Aldrete score of 
10 after a mean period of 11 min (range: 4–22 min).
No significant respiratory depression was noticed. Intra-
operative arterial blood gas analysis confirmed normoxia 
and normocapnia.
Discussion
In the past few years, awake craniotomy has allowed wider 
and safer surgical resections of lesions located in the vicinity 
of functionally relevant areas.
The possibility to easily wake the patients up and neuro-
logically monitor them during surgery is the main advantage 
of this procedure.
However, there is still no consensus or any established 
protocol for the best anesthetic management of such peri-
operative sedation.1
Recently, DEX, a selective alpha-2 receptor agonist, has 
been proposed as the primary sedative–hypnotic drug, as it 
does not depress respiratory drive and it does not interfere with 
electrophysiological testing. Its sedative effects are mediated 
through decreased firing of the locus coeruleus, the main 
noradrenergic nucleus located on the floor of the fourth 
ventricle, and subsequent decrease in noradrenaline release 
in the sympathetic nerves. Such characteristics encourage the 
use of DEX during awake neurosurgical procedures.
However, DEX has well-known adverse effects, such as 
bradycardia and hypotension. These cardiovascular effects 
are dose dependent: with lower infusion rates, the central 
effect predominates, leading to a decrease in HR and blood 
pressure. With higher doses, peripheral vasoconstriction pre-
vails, leading to an increase in systemic vascular resistance 
and blood pressure, while the bradycardic effect is further 
emphasized. Cardiac arrest and respiratory depression have 
also been reported.2,3 Several studies4,5 have extensively 
shown the role of DEX during functional neurosurgery. 
We reviewed the pertinent literature about the use of DEX 
during awake surgery in functionally relevant brain areas.
de Almeida et al6 operated on 3 epileptic patients with 
cavernous angiomas in the speech area using DEX as the 
primary hypnotic drug, without the need to protect airway 
patency. They administered boluses of fentanyl, midazolam, 
PRO, and droperidol during the procedure when judged nec-
essary. In their series, they did not report either significant 
hemodynamic instability or respiratory depression.
Shen et al7 prospectively compared DEX and PRO as 
primary hypnotic drugs during awake craniotomy, performed 
with asleep–awake–asleep protocol. They concluded that 
both DEX and PRO can be effectively and safely adminis-
tered for conscious sedation. However, they found that DEX 
has a shorter arousal time.
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Dexmedetomidine in awake craniotomy
Mohd Nazaruddin et al8 successfully treated 4 patients 
with a combination of DEX and REM intravenous infu-
sions and scalp block with the MAC protocol. They deliv-
ered oxygen to patients only through nasal prongs. Only 
1 patient required supplementary infusion of PRO to achieve 
adequate sedation.
Kallapur and Bhosale9 reported a case of tumor removal 
with awake craniotomy, using scalp block without 3-pin 
holder, with simultaneous infusion of DEX and PRO and 
oxygen delivery through a simple mask. They concluded 
that DEX is a useful adjuvant during awake craniotomy for 
tumor resection.
Chung et al10 performed 6 different anesthetic manage-
ments during awake tumor removal in 6 different patients. 
They simultaneously infused DEX, PRO, and REM in 
2 patients. In 1 case, without airway protection, they did not 
obtain adequate sedation despite a high dose of sedatives. 
In the second patient, they reported good sedation without 
perioperative events, although with the aid of LMA.
Mack et al11 presented a retrospective review of 10 patients 
who received DEX for awake craniotomy. Five of them were 
managed with MAC protocol. They concluded that DEX 
appears to be a useful sedative for awake craniotomy.
In our study, we applied a refined MAC protocol to 
perform awake craniotomy. We obtained adequate sedation 
and analgesia with the simultaneous infusion of DEX, PRO, 
and REM without any loading dose. Using a combination of 
drugs rather than a single drug presents several advantages. 
First, this regimen allows the use of lower PRO doses, thus 
reducing the risk of respiratory depression. Second, DEX 
doses can also be reduced, thus decreasing the risk of car-
diovascular side effects. Third, this analgosedative regimen 
allows spontaneous airway patency without the need for 
tracheal intubation, LMA, or nasal airway, therefore reduc-
ing the risk of cough during the awake period. All patients 
were able to breathe spontaneously.
We did not perform scalp block, despite the use of a 
3-pin head holder. We provided proper local anesthesia by 
injecting only the 3 sites around the pins and the skin inci-
sion. Actually, avoiding scalp block can reduce the risk of 
eventual transient bacteremia due to multiple needle-stick 
injuries, at the same time ensuring a comfortable surgical 
experience to the patient.
After stopping the infusions, all patients experienced 
smooth and rapid awakening. The brain remained 
relaxed throughout the entire procedure. Similarly, we also 
observed stability of hemodynamic parameters during the 
period of neurological monitoring.
Only 3 patients complained of mild pain, successfully 
treated with acetaminophen. Two patients experienced dry 
mouth.
We also observed that a small increase of PRO dose 
during simultaneous infusion of DEX leads to a higher-than-
expected increase of respiratory frequency.
The main limitations of our study are the limited number 
of included patients, as well as the retrospective design of 
the study.
Conclusion
Awake craniotomy entails specific anesthetic management. 
DEX is a unique sedative agent that does not directly cause 
respiratory depression. At the moment, the optimal dose 
regimen of DEX during awake craniotomy is unknown. 
Within the limits of a retrospective study conducted on a 
limited number of patients, we have refined a MAC pro-
tocol combining local anesthesia without scalp block and 
low-dose infusion of DEX, PRO, and REM, with no need 
for airway support. This protocol proved safe and effective 
for this surgery. Nevertheless, prospective randomized trials 
are necessary to confirm the optimal anesthetic technique in 
this setting.
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